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Svelte Stent-on-a-Wire showed vascular healing and tissue response equivalent to that
observed with ML Vision stents.
TCT-448
Scanning Electron Microscopic Observation of Coating Irregularities and Their
Precursors in Unexpanded Durable Polymer-Based Drug-Eluting Stents
Mounir W.Z. Basalus1, Kenneth Tandjung1, Hanim Sen1, Thea van Westen2, Dirk W
Grijpma2, Aart A van Apeldoorn2, Clemens von Birgelen1, 2
1MST hospital, Departement of Cardiology., Enschede, Netherlands; 2MIRA –
Institute for Biomedical Technology and Technical Medicine, University of Twente.,
Enschede, Netherlands
Background: Previous scanning electron microscopy (SEM) studies in expanded DES
revealed differences in the frequency and size of coating irregularities between DES
types and specific distribution patterns, however, the origin of these irregularities is
unclear.The current study quantifies coating irregularities on unexpanded and expanded
durable polymer-based drug-eluting stents (DES) to gain insights into the potential
origin of coating irregularities.
Methods: We assessed at bench side a total of 1200 SEM images obtained in 30 DES
samples (15 expanded and 15 unexpanded) of Cypher Select, Taxus Liberté, Endeavor,
Xience V, and Resolute.
Results: For most types of coating irregularities seen on expanded DES (72%; 23/32),
a matching irregularity (n=18/24) and/or its precursor (n=11/24) was observed in
unexpanded corresponding DES. Only a few individual coating irregularities (13%;
4/32) could not be accessed in unexpanded samples, as these irregularities were located
on the (invisible) luminal side. Unexpanded Cypher Select showed (small) crater
lesions and cracks together with precursors of ‘peeling of polymer’. On unexpanded
Taxus Liberté, thinning of polymer, small bare metal areas, wrinkles and one type of
precursor was found. Unexpanded phosphorylcholine-based Endeavor stents showed
cracks, small bare metal areas, and crater lesions as well as precursors of the latter.
Unexpanded Xience V and Endeavor Resolute mainly revealed crater lesions and their
precursors.
Cypher Stent:Precursor of peelin (left); peeling (right)
Conclusion: SEM assessment demonstrated the presence of various coating
irregularities and/or their precursors on unexpanded durable polymer-based DES.
These findings provide evidence that coating irregularities arise during both DES
manufacturing and stent expansion.
TCT-449
Pre-clinical Evaluation of a Myolimus-Eluting Bioresorbable Polymeric
Scaffold in the Porcine Coronary Artery Model
Guy Leclerc, MD1, Louis-Georges Guy, PhD1, Jean-Martin Lapointe, DVM1, Martin
Laflamme1, Sonida Horng1, Vinayak Bhat, PhD2, Howard Huang2, Anuja Patel2,
John Yan2
1AccelLab Inc, Montreal, Canada; 2Elixir Medical, Sunnyvale, CA
Background: The Polymeric Bioresorbable Myolimus-Eluting Scaffold is a novel drug
eluting device that combines a PLLA-based scaffold coated with a matrix of
bioresorbable polylactide and the drug Myolimus. Myolimus is a macrocyclic lactone
mTOR inhibitor similar to rapamycin (sirolimus) which has demonstrated potent anti-
proliferative properties in cell culture studies and successfully used in two First-in-Man
(FIM) studies on Elixir’s Myolimus eluting coronary stents. The drug dose is 3 mcg
per mm of scaffold length, similar to the dose used in the prior Elixir FIM studies.
Multiple radiopaque markers are located on each end of the scaffold to aid delivery
and placement in vivo. The objective of this study was to evaluate the safety and
efficacy of the Polymeric Bioresorbable Myolimus-Eluting Scaffold in a preclinical
model.
Methods: Polymeric Bioresorbable Myolimus-Eluting Scaffolds were implanted in
swine coronary arteries and evaluated over a period of 28, 90 and 180 days. Analyses
by OCT and histopathology were employed to evaluate the safety and efficacy of the
scaffolding systems. Pharmacokinetics (PK) of the drug from the scaffold was
measured using standard analytical techniques.
Results: The preclinical results of the Polymeric Bioresorbable Myolimus-Eluting
Scaffold implanted in the porcine coronary artery model are presented in the table
below. All vessels were patent after the evaluation period with histopathology profiles
expected for drug eluting stents. The PK analysis of the scaffold and tissue surrounding
the scaffold showed that approximately 80% of drug is released over a 28 day period.
Conclusion: The preclinical evaluation of the Polymeric Bioresorbable Myolimus-
Eluting Scaffold demonstrated safety and effectiveness in support of a First-in-Man
study.
TCT-450
Insights from Network Analysis: Deficiency of Glutathione Peroxidase-1
Increases In-stent Stenosis
Ziad A Ali, Azad Raiesdana, Xiumei Qu, Sanjay Patel, Farshad Keyghobadi, Amber
Saeed, Thomas Quertermous, Euan Ashley
Cardiovascular Medicine, Stanford University, Stanford, CA
Background: Deficiency of the glutathione peroxidase-1 (GPx1) is associated with
in-stent stenosis (ISS).
Methods: We used a novel genome-wide gene expression network approach in human
atherectomy samples comparing atherosclerosis to ISS (n=89) to identify signaling
networks critical to the process of ISS. We found that a subnetwork with GPx1 as its
hub was among the most significantly differentially regulated (Fig 1, bar thickness
denotes association strength). We investigated the importance of Gpx1 in ISS using
knockout mice with constitutive deficiency of GPx1 crossed onto atherosclerotic ApoE-
KO background using a novel model of balloon angioplasty and stenting (BAS) in
mice.
Results: ApoE-KO mice had significantly decreased Gpx1 expression compared to
atherosclerosis. Despite equal stent expansion and injury scores, ISS was increased by
50% on histological cross-section (P<0.01) and 33% per-stented vessel longitudinally
by OCT (P<0.01) in GPx1/ApoE-KO mice 28 days following BAS (Fig 2, white arrows
denote neointima). In keeping with this, both proliferation (71%, P<0.01) and migration
(90%, P<0.01) were significantly increased in GPx1/ApoE-KO primary aortic smooth
muscle cells compared to ApoE-KO. In animals with additional targeted endothelial
reporter gene expression (Tie2-LacZ) we found Gpx1/ApoE-KO/LacZ mice had
significantly reduced endothelial coverage (58%, P=0.03) compared with ApoE-
KO/LacZ mice, suggesting impaired reendothelialization as a potential mechanism by
which Gpx1/ApoE-KO mice have increased ISS.
Conclusion: Using a network analysis approach we have identified an important role
for GPx1 signaling in vascular wall redox processes critical to ISS.
TCT-451
Right through the Heart - Transseptal Access for Stent-Graft placement in the
Ascending Aorta
Sabine Helena Wipper, Christina Lohrenz, Klaas Peymann, Eike S Debus, Tilo
Kölbel
Department of vascular medicine, University Heart Center Hamburg, Hamburg,
Germany
Background: Transseptal access is routinely used for cardiological procedures in the
left heart, but not yet to access the aortic arch and its branches. Iliac and aortic
pathology such as obstruction and tortuosity may require antegrade access to advance
and deploy an endograft in the proximal parts of the thoracic aorta. The aim of the
present study was to test the feasibility of antegrade transseptal access to the ascending
aorta for stent-graft introduction and placement using a through-and-through guidewire
technique in a porcine model.
Methods: Transseptal puncture was performed in 6 domestic pigs (51-58kgBW) from
the inferior vena cava for guidewire-passage across the left heart to the descending
aorta to establish transseptal through-and-through access. Custom-made endografts
consisting of polyester-tube and two nitinol-stents (diameter 24mm, length of 32mm)
were advanced using the transvenous antegrade access and deployed under fluoroscopy
into the ascending aorta using a pull-and-push technique with moderate tension on the
wire. Hemodynamic monitoring (PiCCo catheter, Swan-Ganz catheter), transit-time
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flow measurement of the carotid artery, myocardial and cerebral perfusion using
fluorescent microspheres were performed during baseline (M1), sheath forwarding
(M2), stent-graft deployment (M3) and after retraction of the sheath (M4) for
evaluation of hemodynamic changes during transseptal deployment and concomitant
myocardial and cerebral perfusion deficiency.
Results: Stent graft deployment into the ascending aorta was feasible in all six animals.
Coronary arteries were patent in all cases confirmed by fluoroscopy. In four animals
(66%) the innominate artery was partially occluded reflected by reduced carotid blood-
flow. During advancing of the stent-graft transient hemodynamic instability due to
severe mitral valve insufficiency occurred in all animals (M2, M3), after retrieval of
the delivery-system (M4) hemodynamic stability recovered within ten minutes in all
animals.
Conclusion: Transseptal access to the ascending aorta in a porcine model is feasible.
Transient hemodynamic instability recovered to near preoperative values. Assessment
of cerebral and myocardial perfusion for evaluation of the severity of the periprocedural
deterioration using fluoresecent microspheres is under evaluation. Antegrade
transseptal stentgraft deployment might be a promising tool.
TCT-452
Increased Endothelial Tetrahydrobiopterin Reduces In Stent Stenosis in
Apolipoprotein E-Knockout Mice
Ziad A Ali1, 2, Gillian Douglas2, Nicholas J Alp2, Henry Lupton2, Keith M Channon2
1Cardiovascular Medicine, Stanford University, Stanford, CA; 2Oxford University,
Oxford, United Kingdom
Background: In-stent stenosis, the principal cause PCI failure, is associated with
reduced endothelial nitric oxide (NO) bioavailability. Tetrahydrobiopterin (BH4) is a
required cofactor for NO synthesis by endothelial nitric oxide synthase (eNOS).
Methods: We investigated the importance of BH4 in regulating eNOS activity in in-
stent stenosis using a transgenic mouse with endothelial overexpression of the
rate-limiting enzyme in BH4 synthesis, GTP-cyclohydrolase I (GCH). Thoracic aortic
segments which underwent balloon angioplasty and stenting from donor transgenic
mice crossed onto ApoE-KO background (GCH-Tg/ApoE-KO) or their ApoE-KO
littermates were grafted onto the carotid artery of isogenic recipients.
Results: Aortic BH4 levels were 8-fold higher in GCH-Tg/ApoE-KO mice compared
to ApoE-KO controls (P<0.01). Despite equal stent expansion and injury scores, in-
stent stenosis was reduced by 47% (P<0.001) in GCH-Tg/ApoE-KO mice. NO
synthesis, measured using arginine to citrulline conversion and electron paramagnetic
resonance in aorta of experimental animals, was not different between groups.
However, O2- production was significantly attenuated in GCH-Tg/ApoE-KO mice
measured on both aortic sections using oxidative confocal microtopography and whole
aorta by lucigenin enhanced chemiluminescence. eNOS inhibition by L-NAME
reversed these effects indicating that under basal conditions GCH-Tg/ApoE-KO mice
had preserved eNOS coupling promoting NO synthesis.
Conclusion: These results indicate that a reduction in-stent stenosis is conferred by
maintaining eNOS coupling and reducing O2- production. These findings highlight
the importance of eNOS function in in-stent stenosis.
TCT-453
Early Enzymatic Infarct Size Assessment using Heart Specific Fatty Acid
Binding Protein
André Uitterdijk1, Stefan Sneep1, Richard van Duin1, Ilona Krabbendam-Peters1,
Ayla Hoogendoorn1, Charlotte Gorsse-Bakker1, Dirk Duncker1, Willem J van der
Giessen1, 2, Heleen M van Beusekom1
1Thoraxcenter, Cardiology, Erasmus MC, 3000CA Rotterdam, Netherlands;
2Erasmus MC and ICIN KNAW, Rotterdam - Utrecht, Netherlands
Background: In clinical practice, myocardial necrosis (MN) is determined by Troponin
(Trop) which can be detected only several hours after onset of ischemia. In search for
early specific and accurate biomarkers to determine MN and quantify infarct size (IS),
we evaluated heart specific fatty acid binding protein (hFABP), a small cytosolic,
cardiac specific marker released during acute myocardial infarction (AMI) ±
reperfusion (R) in comparison to Trop and morphometric triphenyl tetrazolium chloride
infarct size determination (TTC).
Methods: In 8 swine, AMI was induced by 8 hr chronic balloon occlusion (C) or 2 hr
balloon occlusion followed by 6 hr reperfusion (R). Blood samples were taken at
predetermined intervals and analyzed for hFABP and high sensitivity Troponin I (Trop
I). TTC was used to determine IS.
Results: In AMI-C hFABP was detected faster than Trop upon occlusion (90±35 vs.
188±62 min, mean ± SD, p<0.04) with peak values at 5±1 hr. Trop I did not reach peak
levels in 8 hr. Area under Curve (AUC) for hFABP and Trop I did not correlate strongly
with IS (R2 =0.57 vs. 0.34). In AMI-R (Fig.), hFABP increased immediately upon
reperfusion while Trop I was delayed 20±15 min. (p=0.03). hFABP peak values were
reached in 38±15 min after R, Trop. I in 145±15min. (p<0.001). IS by TTC correlated
well with 8 hr AUC both for both markers (R2=0.90). However, hFABP reperfusion
peak values (Fig.) showed the highest correlation (R2=0.98 vs. 0.87). Moreover the
intercept value of the trendline nearly coincides with mean baseline hFABP values.
Conclusion: H-FABP release rises significantly faster and correlates better with IS
than Trop I in a large animal ischemia-reperfusion model. Maximal hFABP release can
be measured within 1 hr upon reperfusion or 5 hr in chronic MI. Taken together, hFABP
is an accurate and very fast biomarker for longitudinal in vivo measurement of infarct
size in a swine.
TCT-454
A Highly Reproducible and Clinically Relevant Large Animal Model of
Myocardial Ischemia and Heart Failure as Determined by MRI Imaging
Michael Brendan Sweet1, Traci Goodchild1, Stephen Frohwein2, Ross Hutchison1,
Robert Matheny3, Nicolas Chronos1, Jaipal Singh1
1Saint Joseph’s Translational Research Institute, Atlanta, GA; 2Saint Joseph’s
Hospital, Atlanta, GA; 3CorMatrix, Marietta, GA
Background: Acute myocardial infarction (AMI) and heart failure remain the leading
cause of death in United States. Availability of a reproducible large animal model with
a large infarction and ejection fraction below 35% is highly desirable for the evaluation
of novel myocardial regenerative therapies including cell therapy, injectable matrices,
cardiac resynchronization therapy (CRT), and CRT-drug combinations. The goal was
to develop a reproducible swine model of myocardial infarction and heart failure with
average ejection fraction (EF) below 35%.
Methods: A total of 18 Yucatan miniature pigs underwent minimally invasive closed-
chest induction of AMI by percutaneous infusion of collagen gel into the left anterior
descending coronary artery (LAD) and side branches under fluoroscopic guidance.
Complete occlusion of the LAD and side branches was confirmed and maintained over
2hrs as assessed by coronary angiography. After 3 months, cardiac function was
evaluated in surviving pigs (12 of 18) and one naïve uninfarcted Yucatan pig as control
using a 1.5T MRI System (MR143 Siemens Magnetom Avanto). Analysis was
performed using Circle Cardiovascular Imaging’s CMR42 software. Left ventricular
volumes at end systole (LVESD) and diastole (LVEDD), ejection fraction (EF), and
wall thickness (WT) in the area at risk (AAR) and normal zone (NZ) were calculated.
Results: LVESV and LVEDV in the infarcted pigs were 4- and 2-fold higher,
respectively, compared to control. EF was reduced in infarcted pigs compared to control
(27.0± 2.3 vs. 59.9%, respectively). WT in AAR and NZ were reduced by 6- and 2-
fold, respectively, in infarcted pigs compared to control.
Conclusion: We have shown that percutaneous infusion of collagen gel into the porcine
coronary circulation generates large myocardial infarctions associated with severe
cardiac dysfunction and EF below 35%. This highly reproducible model is an important
tool for testing of therapies for AMI and congestive heart failure.
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